The FDA expanded the approval of pemetrexed for injection to include its use in combination with pembrolizumab and platinum chemotherapy for first-line treatment of metastatic nonsquamous non-small cell lung cancer.

The approval applies to patients with no epidermal growth factor receptor or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.